A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy - Wikidata - awgldk - TriplyDB

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

http://www.wikidata.org/entity/Q28287088

about

RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action Non-coding landscapes of colorectal cancer Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients Tumor suppressor microRNAs: a novel non-coding alliance against cancer MiRNAs and miRNA Polymorphisms Modify Drug Response Genetic variation in a hsa-let-7 binding site in RAD52 is associated with breast cancer susceptibility SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients Role of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population.The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab MicroRNA-mediated regulation of KRAS in cancer Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905 Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer.RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells.Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.The role of microRNAs in colorectal cancer.Prognostic significance of microRNA gene polymorphisms in patients with surgically resected colorectal cancer.Circulating small non-coding RNA signature in head and neck squamous cell carcinoma A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer.Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics.Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer.MicroRNA-related sequence variations in human cancers.MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk.MicroRNAs in colorectal cancer metastasis.Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.MicroRNAs: relevant tools for a colorectal surgeon?Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?

P2860

Q26773479-2D2096FA-E996-43D8-A678-D5D96A386ACC Q26778014-BDB5CE28-E3FB-4330-A3BE-D4D762A88B50 Q26827474-2C8C8591-EF13-4EA2-8DFE-21A864580449 Q26865275-1216316F-02A4-4757-B818-12CDE34F60C0 Q26995383-88C4C5D8-2016-44DA-8F61-D4786F4BF064 Q28079075-B9A3F85F-5D58-4120-BB3D-AE0D1E5B8003 Q28280159-2CD7E402-C278-4708-B2F9-F86597BA5375 Q33640984-0F2548B6-5615-4B2F-B52F-C8A8A7D20CC0 Q33720978-8A5E6C3D-64E2-41E0-98F2-A837A2F36571 Q33855053-EC0FEB3E-B8D9-4650-BAC1-B4471F1B8B4B Q33861210-5CF1DE2A-2C0A-4DBE-8303-12FA83356736 Q34072487-507998E2-8BC8-48DA-93F4-1C2821F95E2F Q34134870-8CD34502-8D61-4978-9B20-FAE663860E60 Q34138308-C135C808-CDF8-4EF4-A328-3DA0A387677C Q34227531-C0410F62-1344-426C-9231-613DCB8874F6 Q34483581-8C40D26A-DF8E-4868-95B9-8BE7FAD4F0B0 Q34678120-53780A90-2C78-45B5-8765-ED7196977C1F Q34990394-B55ED3EC-7B1D-4894-B561-688A4F1C6586 Q35147597-EB995FB8-9FD1-4E38-91A5-0109CEF83583 Q35561695-E533AE1D-DEBE-470D-AFCF-545B8770E443 Q35888467-B6803BFD-C276-4959-9EB7-0DB23CCEFB4B Q35998435-3844A29C-4852-49D8-B822-7BDEF84C764E Q36000232-6BD5EF87-CB1C-42A1-826C-0D372BE89E6E Q36051517-489EF801-F7EB-4482-9725-2D7C8F46C164 Q36096641-B5D8FE1D-8D0C-404A-B61A-2DE9DF3F3CF2 Q36230905-086C944E-0A33-4526-BA11-220E791A41DD Q36326374-F3BF4791-77A4-4529-8F5C-D441DA7EB9D3 Q36369415-D05C4C62-9B94-4D09-89C6-FF520187E832 Q36502358-13F313EA-5FDB-43CD-A8A1-3EE532157E00 Q36605121-E6FE318E-695B-46A6-81A0-83D925E7AF53 Q37295196-8668E76A-EEEE-4EA0-920E-6DEF4F9EBB72 Q37577068-84199BB9-C4D4-4573-9EBA-C772A37D9669 Q37608685-52EC2D29-A683-4C94-B2D7-C35C8DD327EB Q37636207-8FC46375-A16D-48DD-8086-ACB47F426B80 Q37833066-C3A9CCDD-F611-4666-B13B-C0AD7572B468 Q37894616-69A1E506-927D-464B-8BFA-17478D7D1608 Q37969851-D4FDCAB8-E6E2-4CD7-B123-52F183BBE9B7 Q38004774-F373832B-F0FC-4C9D-AAED-4631E2EC8839 Q38021921-E924EC5D-BB7F-4C1B-B393-5E911DD121DF Q38059508-289CC75F-65A8-48F2-BE63-981AB92D61B7

P2860

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

http://www.wikidata.org/entity/Q28287088

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@ast

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@en

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@nl

type

label

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@ast

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@en

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@nl

prefLabel

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@ast

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@en

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@nl

P1433

Q28287088-A58A16F3-3B70-4BF5-8B41-37CC1B511142

P1476

Q28287088-44D2C61C-652C-4B9D-958E-5CF8DE15C9CD

P2093

Q28287088-09378EEB-169A-471A-A161-549C50DB21CF

Q28287088-1E5678D4-3CF0-4B2F-BCD7-AE65077B38CD

Q28287088-32C1EE75-D9B3-46D1-8180-3D6A26D45191

Q28287088-619C4693-BB21-4E09-8970-7BD32187A185

Q28287088-715AD078-BA1F-4AE5-A889-FB8B4E7EEC7D

Q28287088-723B3DF2-D365-4523-BED7-09B0AF0D8CFA

Q28287088-A6EA12A8-017B-4FD6-AC23-9B3B165B0271

Q28287088-B0277D15-3ECC-4464-A0EE-B774D2D91952

Q28287088-B547DA90-698A-4D04-92A2-385F27B83C49

Q28287088-D373832E-89C1-471B-AC59-B71FE5384615

P2860

Q28287088-027EE7B4-B65A-4CF2-BDD2-7DA6D787EBDD

Q28287088-0AA57832-0D0B-48F8-BB53-EFD8DA9A854B

Q28287088-130FD2F3-E993-4D71-ABA8-3DAA73691434

Q28287088-2A364A11-7136-472F-8F69-41BF9BD92B86

Q28287088-38ED433A-0687-4D00-AE0C-9CB5F0E9EC6E

Q28287088-3A8A0C90-6811-48F1-9833-068856F61141

Q28287088-465CBAFE-0EE3-4F28-837C-0BA5622F2DBB

Q28287088-575C88FA-9E06-4B6D-959C-61B2D5780101

Q28287088-58D70A9B-17B0-4CA9-A3D1-BA81FA50032D

Q28287088-58DD9F07-A003-4DAD-A3CE-F8953053AB33

P304

Q28287088-CC8785F3-0256-46D3-BB5A-E797FAEA0374

P31

Q28287088-72FE4759-BF6C-434A-8132-84F50350AAAD

P356

Q28287088-33522F12-25CB-488C-912D-CBF9983FBF75

P407

Q28287088-663818DF-92A4-442D-A96B-F86395083157

P433

Q28287088-8FB1B085-BCCF-4A69-8DD0-BDD1B93D9269

P478

Q28287088-A30FD97C-EDFC-4109-8D70-BE6813E9239B

P577

Q28287088-0724D533-3D8A-47A9-B963-3EEC8B821D4C

P5875

Q28287088-FDA04A14-0EB0-47E5-A1A4-8A545EC90E37

P698

Q28287088-D761253F-E5F9-4A52-9053-018FA0DFA932

P921

Q28287088-5F6CDD9C-1CC9-49AF-A0DC-C0A806BB0E71

Q28287088-BCB721C6-C0FB-472D-90D1-2ECB3D850DB7

Q28287088-E1AE9BB7-FCA1-490B-B84F-59E557A9FA39

P356

P1433

Annals of Oncology

P1476

A let-7 microRNA-binding site ...... ted with cetuximab monotherapy

@en

P2093

A Pohl

http://www.w3.org/2001/XMLSchema#string

C Langer

http://www.w3.org/2001/XMLSchema#string

D J Mauro

http://www.w3.org/2001/XMLSchema#string

D Yang

http://www.w3.org/2001/XMLSchema#string

E K Rowinsky

http://www.w3.org/2001/XMLSchema#string

G Lurje

http://www.w3.org/2001/XMLSchema#string

H-J Lenz

http://www.w3.org/2001/XMLSchema#string

M A Gordon

http://www.w3.org/2001/XMLSchema#string

M J Labonte

http://www.w3.org/2001/XMLSchema#string

M Kahn

http://www.w3.org/2001/XMLSchema#string

P2860

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Cetuximab for the treatment of colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

RAS is regulated by the let-7 microRNA family

let-7 microRNA functions as a potential growth suppressor in human colon cancer cells

P304

104-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ315

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45094473

http://www.w3.org/2001/XMLSchema#string

P698

20603437

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer